Table 3.
Predicting value for 5-year mortality in IPF patients assessed by Cox proportional hazards model
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Serum (n = 79) | ||||||
| Age, years | 0.99 | 0.95–1.04 | 0.680 | – | – | – |
| Sex, Male/Female | 1.16 | 0.27–4.98 | 0.648 | – | – | – |
| Smoking history, pack-years | 1.00 | 0.98–1.01 | 0.825 | – | – | – |
| FVC, % predicted | 0.94 | 0.91–0.98 | < 0.001* | 0.94 | 0.91–0.98 | 0.002* |
| Serum esRAGE, ng/ml | 0.99 | 0.98–0.99 | 0.019* | 0.99 | 0.98–0.99 | 0.028* |
| BALF (n = 57) | ||||||
| Age, years | 1.02 | 0.97–1.08 | 0.474 | – | – | – |
| Sex, Male/Female | 0.94 | 0.12–7.09 | 0.953 | – | – | – |
| Smoking history, pack-years | 0.99 | 0.97–1.01 | 0.330 | – | – | – |
| FVC, % predicted | 0.96 | 0.93–0.99 | 0.009* | 0.96 | 0.92–0.99 | 0.020* |
| BALF esRAGE, ng/ml | 0.99 | 0.99–0.99 | 0.009* | 0.99 | 0.98–0.99 | 0.041* |
* p < 0.05 Cox proportional hazards model
esRAGE endogenous secretory receptor for advanced glycation end products, BALF bronchoalveolar lavage fluid, CI confidence interval, IPF idiopathic pulmonary fibrosis, HR hazard ratio, FVC forced vital capacity